Otsuka is voluntarily recalling certain lots of ABILIFY® (aripiprazole) Tablets due to cross-contamination from extremely small amounts of another active pharmaceutical ingredient previously manufactured on the same equipment. Based on sample testing performed, there is no material patient risk associated with the trace level of contamination found. The voluntary recall has been initiated by Otsuka out of an abundance of caution, with the knowledge of the U.S. Food and Drug Administration. This recall is limited to the United States.

Consumers who have a product that is being recalled and who have concerns, should consult with their healthcare provider or pharmacy. Adverse reactions or quality problems experienced with the use of this product should be reported.

Otsuka America Pharmaceutical, Inc. can be reached by phone at 1-833-468-7852 Monday – Friday, 9 a.m. – 5 p.m. Eastern Time or by email: global_intake@otsuka-us.com or ProductComplaints@otsuka-us.com. The FDA's MedWatch Adverse Event Reporting program can be reached either online or by phone. To complete and submit the report Online: www.fda.gov/medwatch/report.htm or call 1-800-332-1088.

Read more here: https://www.otsuka-us.com/news/otsuka-us-voluntary-recall

April 2024 01US24EBC0008

As President & General Manager of Otsuka Canada, Mike is a 20-year veteran in the pharmaceutical industry and a distinguished leader. Mike has been integral to Otsuka’s growing presence in both the mental health and nephrology space and exemplifies Otsuka’s purpose to defy limitation, so that others can too. Mike works to shape the OCPI organization by managing all functional areas and building business priorities, establishing key metrics, and ensuring infrastructure and company expansion to bring therapeutic solutions to patients in need.

Mike joined Otsuka in September 2010 as Country Executive Director (Market Access, Commercial Operations, Finance & Administration) where he developed and executed strategies to address complex and challenging issues within the pharmaceutical industry. He was responsible for the pricing and reimbursement, commercial operations, supply chain, human resources, information technology, and  finance & administration functions. Prior to Otsuka, Mike served as the Director of Business Planning & Analysis at Novartis.

Mike earned his Bachelor of Commerce in Accounting and a Minor in Business Law at Concordia University. He later received a Graduate Diploma in Accounting and went on to become an Adjunct Professor at Concordia’s John Molson School of Business.

Otsuka’s unique culture places diversity of thought at our core—and our people are forever learning, growing and re-inventing themselves on our path towards innovation and impact.